β-adrenoreceptors and the risk of Parkinson's disease
- 27 January 2020
- journal article
- review article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 19 (3), 247-254
- https://doi.org/10.1016/s1474-4422(19)30400-4
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Meta‐analysis of early nonmotor features and risk factors for Parkinson diseaseAnnals of Neurology, 2012
- Essential tremor and Parkinson's disease: Lack of a linkMovement Disorders, 2011
- Adrenoceptors in brain: Cellular gene expression and effects on astrocytic metabolism and [Ca2+]iNeurochemistry International, 2010
- Statin use and Parkinson's disease in DenmarkMovement Disorders, 2010
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseThe New England Journal of Medicine, 2009
- β-Blocker Use for the Stages of Heart FailureMayo Clinic Proceedings, 2009
- Use of Statins and the Risk of Parkinson???s DiseaseDrug Safety, 2008
- β blockers in hypertension and cardiovascular diseaseBMJ, 2007
- Calcium channel blockers and β-blockers in relation to Parkinson's diseaseParkinsonism & Related Disorders, 2007
- Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsideredMovement Disorders, 2006